And the 2009 IPO class grows with the announced filing of Durham, NC-based Aldagen. The post title is a poor attempt at a double entendre – the Company had previously filed their S-1 for a planned public offering approximately 12 months ago (updated filing is [HERE]), and their business model focuses on regenerative cell therapies, [...]

• 601http://clsdf.com/2009/11/aldagen-regenerative-ipo-filing/Aldagen+%7C+Regenerative+IPO+Filing2009-11-03+15%3A38%3A07admin

NOTE: Apologies for the delayed post release. 22″ of October snow yielded a slow start to the day… Waltham, MA-based Synageva Biopharma (formerly AviGenics) is focused on novel, next-generation and follow-on protein therapeutics that leverage their Synageva Expression Platform (SEP™). SEP™ is an integrated platform of proprietary vectors and protein production, processing and purification systems [...]

• 561http://clsdf.com/2009/10/synageva-biopharma-series-c-45m/Synageva+BioPharma+%7C+Series+C+%2445M2009-10-29+17%3A55%3A15admin

Lux Biosciences, based in Jersey City, NJ and focused upon the development of ophthalmic disease, has relied upon an in-licensing strategy from corporate partners and academia for molecules and technologies that have demonstrated proof-of-concept in related non-ophthalmic diseases but where common mechanisms of action and biological pathway overlap may be levered. PRODUCTS IN DEVELOPMENT LX211, [...]

• 510http://clsdf.com/2009/10/lux-biosciences-series-b-50m/Lux+Biosciences+%7C+Series+B+%2450M2009-10-21+14%3A52%3A57admin

There is some robust and diverse activity transpiring at West Lafayette, IN-based Endocyte where not one, not two but three unique business activities are transpiring concurrently. These include: Addressing the issues of dosing and toxicity of oncologic therapeutics via a drug guidance system which is intended to improve specificity, safety and efficacy, and is payload [...]

• 502http://clsdf.com/2009/10/endocyte-series-c-26m/Endocyte+%7C+Series+C+%2426M2009-10-20+14%3A33%3A50admin